5,6-Dimethylxantheonone-4-acetic acid
| Title | Journal |
|---|---|
| p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. | The Journal of pharmacology and experimental therapeutics 20120601 |
| DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. | Clinical science (London, England : 1979) 20120501 |
| Mass balance, excretion and metabolism of [¹⁴C] ASA404 in cancer patients in a phase I trial. | Cancer chemotherapy and pharmacology 20120501 |
| Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA. | British journal of cancer 20120313 |
| Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. | Molecular cancer therapeutics 20120201 |
| High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. | PloS one 20120101 |
| The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. | BMC cancer 20120101 |
| Vascular disrupting agent drug classes differ in effects on the cytoskeleton. | PloS one 20120101 |
| Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging. | Angiogenesis 20111201 |
| Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. | British journal of cancer 20111108 |
| Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. | Biochemical pharmacology 20111101 |
| Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. | Journal of cancer research and clinical oncology 20111101 |
| Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). | Expert opinion on drug metabolism & toxicology 20111001 |
| Pharmacologic activation of the innate immune system to prevent respiratory viral infections. | American journal of respiratory cell and molecular biology 20110901 |
| The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. | Japanese journal of clinical oncology 20110901 |
| Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801 |
| Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801 |
| Cardiovascular toxicity profiles of vascular-disrupting agents. | The oncologist 20110801 |
| Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. | Human gene therapy 20110701 |
| Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses. | Photochemistry and photobiology 20110701 |
| Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701 |
| Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer. | Clinical lung cancer 20110501 |
| Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. | Cancer science 20110401 |
| The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. | Journal of leukocyte biology 20110301 |
| 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110301 |
| Editorial: One small molecule: a new way to treat the flu? | Journal of leukocyte biology 20110301 |
| Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. | Journal of biomedical science 20110101 |
| Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. | BMC medical genomics 20110101 |
| Flavonoids: A versatile source of anticancer drugs. | Pharmacognosy reviews 20110101 |
| Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. | Journal of thoracic disease 20101201 |
| Temporal aspects of the action of ASA404 (vadimezan; DMXAA). | Expert opinion on investigational drugs 20101101 |
| ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. | Future oncology (London, England) 20101001 |
| Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. | Neoplasia (New York, N.Y.) 20100901 |
| Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. | British journal of cancer 20100824 |
| Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid. | Acta crystallographica. Section E, Structure reports online 20100801 |
| RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. | European radiology 20100601 |
| Guidelines for the welfare and use of animals in cancer research. | British journal of cancer 20100525 |
| Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100515 |
| Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. | Cancer 20100415 |
| Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). | The Journal of biological chemistry 20100402 |
| Novel agents target existing tumor vasculature. | Expert review of anticancer therapy 20100301 |
| [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100301 |
| The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. | Expert opinion on investigational drugs 20100201 |
| Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. | Journal of oncology 20100101 |
| Molecule of the month. Vadimezan. | Drug news & perspectives 20091101 |
| Molecular imaging of hypoxia with radiolabelled agents. | European journal of nuclear medicine and molecular imaging 20091001 |
| AVE8062: a new combretastatin derivative vascular disrupting agent. | Expert opinion on investigational drugs 20091001 |
| Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer. | Translational oncology 20090818 |
| Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20090801 |
| MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20090801 |
| Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). | Neoplasia (New York, N.Y.) 20090801 |
| Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. | Investigational new drugs 20090601 |
| Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. | Investigative ophthalmology & visual science 20090601 |
| Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. | The oncologist 20090601 |
| The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. | Photochemistry and photobiology 20090101 |
| Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA. | International journal of oncology 20090101 |
| Indexing TNF-alpha gene expression using a gene-targeted reporter cell line. | BMC biology 20090101 |
| Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation. | Oxidative medicine and cellular longevity 20090101 |
| Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. | British journal of cancer 20081209 |
| Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors. | International journal of radiation oncology, biology, physics 20081115 |
| ASA404: update on drug development. | Expert opinion on investigational drugs 20081001 |
| [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. | Magyar onkologia 20080901 |
| Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. | International journal of radiation oncology, biology, physics 20080801 |
| Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. | Journal of immunology (Baltimore, Md. : 1950) 20080515 |
| Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. | Oncology reports 20080401 |
| Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080401 |
| Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. | Cancer chemotherapy and pharmacology 20080301 |
| IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20080301 |
| The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. | Expert opinion on investigational drugs 20080101 |
| The ability of coumarin-, flavanon- and flavonol-analogues of flavone acetic acid to stimulate human monocytes. | Oncology reports 20080101 |
| Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. | Molecular cancer 20080101 |
| The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. | International journal of radiation oncology, biology, physics 20071115 |
| Early experience with novel immunomodulators for cancer treatment. | Expert opinion on investigational drugs 20070901 |
| Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling. | Journal of medicinal chemistry 20070809 |
| The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. | Cancer research 20070715 |
| The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. | The Journal of experimental medicine 20070709 |
| N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice. | British journal of cancer 20070604 |
| Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Investigational new drugs 20070601 |
| Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601 |
| Vascular disrupting agents in clinical development. | British journal of cancer 20070423 |
| Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. | Cancer chemotherapy and pharmacology 20070401 |
| Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. | Cancer chemotherapy and pharmacology 20070401 |
| Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. | Neoplasia (New York, N.Y.) 20070201 |
| DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. | British journal of cancer 20070129 |
| NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. | Anticancer research 20070101 |
| Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia. | Molecular imaging 20070101 |
| Vascular disrupting agents. | Journal of cellular biochemistry 20061101 |
| 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy. | Immunology and cell biology 20060801 |
| Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. | Neoplasia (New York, N.Y.) 20060701 |
| New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-alpha and NO production by human immune cells. | Bioorganic & medicinal chemistry 20060615 |
| Current development status of small-molecule vascular disrupting agents. | Current opinion in investigational drugs (London, England : 2000) 20060601 |
| 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060315 |
| Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. | Neoplasia (New York, N.Y.) 20060301 |
| The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. | Acta oncologica (Stockholm, Sweden) 20060101 |
| Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. | Oncology research 20060101 |
| Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. | Cancer research 20051215 |
| Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005? | Clinical lung cancer 20051101 |
| Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. | British journal of cancer 20051031 |
| Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA). | Current medicinal chemistry. Anti-cancer agents 20050901 |
| Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. | International journal of cancer 20050820 |
| Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study. | Clinical and experimental pharmacology & physiology 20050801 |
| Disrupting tumour blood vessels. | Nature reviews. Cancer 20050601 |
| Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050601 |
| Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050515 |
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. | British journal of cancer 20050509 |
| Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050401 |
| Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. | Current oncology reports 20050301 |
| Mono- or di-fluorinated analogues of flavone-8-acetic acid: synthesis and in vitro biological activity. | Anticancer research 20050101 |
| A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. | Oncology research 20050101 |
| Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925 |
| Vascular-targeting therapies for treatment of malignant disease. | Cancer 20040615 |
| Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20040601 |
| Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor. | Cancer chemotherapy and pharmacology 20040501 |
| Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. | Biochemical pharmacology 20040301 |
| Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. | British journal of cancer 20040223 |
| Vascular targeting agents as cancer therapeutics. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040115 |
| Angiogenesis inhibitors in clinical development; where are we now and where are we going? | British journal of cancer 20040112 |
| Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031215 |
| Clostridia in cancer therapy. | Nature reviews. Microbiology 20031201 |
| Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. | Cancer research 20031115 |
| Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid. | Journal of medicinal chemistry 20030814 |
| Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. | British journal of cancer 20030804 |
| Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. | British journal of cancer 20030616 |
| Requirements for ICAM-1 immunogene therapy of lymphoma. | Cancer gene therapy 20030601 |
| Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. | Biochemical pharmacology 20030601 |
| Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. | British journal of cancer 20030519 |
| NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | European journal of cancer (Oxford, England : 1990) 20030501 |
| 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. | British journal of cancer 20030422 |
| Early detection of tumour immune-rejection using magnetic resonance imaging. | British journal of cancer 20030407 |
| The first international conference on vascular targeting: meeting overview. | Cancer research 20030301 |
| Antivascular therapy of cancer: DMXAA. | The Lancet. Oncology 20030301 |
| Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. | Biochemical pharmacology 20030101 |
| Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Cancer chemotherapy and pharmacology 20030101 |
| Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Oncology research 20030101 |
| DMXAA: an antivascular agent with multiple host responses. | International journal of radiation oncology, biology, physics 20021201 |
| Combination of vascular targeting agents with thermal or radiation therapy. | International journal of radiation oncology, biology, physics 20021201 |
| Enhancement of radiation therapy by vascular targeting agents. | Current opinion in investigational drugs (London, England : 2000) 20021101 |
| Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. | Drug metabolism reviews 20021101 |
| Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid. | Journal of medicinal chemistry 20021024 |
| Potential of DMXAA combination therapy for solid tumors. | Expert review of anticancer therapy 20021001 |
| An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | European journal of medicinal chemistry 20021001 |
| Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915 |
| Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020905 |
| The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. | British journal of cancer 20020812 |
| 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. | Investigational new drugs 20020801 |
| Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. | The Journal of pharmacy and pharmacology 20020701 |
| Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. | British journal of cancer 20020617 |
| A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. | British journal of cancer 20020520 |
| Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. | International journal of cancer 20020501 |
| Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy. | Neoplasia (New York, N.Y.) 20020501 |
| Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. | NMR in biomedicine 20020401 |
| Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. | NMR in biomedicine 20020401 |
| High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020205 |
| Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Cancer chemotherapy and pharmacology 20020201 |
| Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. | Xenobiotica; the fate of foreign compounds in biological systems 20020201 |
| Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice. | Cancer chemotherapy and pharmacology 20020101 |
| Thalidomide in cancer treatment: a potential role in the elderly? | Drugs & aging 20020101 |
| 6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. | European journal of drug metabolism and pharmacokinetics 20020101 |
| Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. | Oncology research 20020101 |
| Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. | Clinica chimica acta; international journal of clinical chemistry 20011201 |
| Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. | Radiation research 20011101 |
| The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. | European journal of cancer (Oxford, England : 1990) 20011001 |
| Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. | British journal of clinical pharmacology 20010801 |
| Small-molecule cytokine inducers causing tumor necrosis. | Current opinion in investigational drugs (London, England : 2000) 20010701 |
| Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010615 |
| Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. | Journal of chromatography. B, Biomedical sciences and applications 20010615 |
| Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Cancer chemotherapy and pharmacology 20010601 |
| A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. | Cancer chemotherapy and pharmacology 20010601 |
| Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. | Xenobiotica; the fate of foreign compounds in biological systems 20010501 |
| Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. | The Journal of pharmacy and pharmacology 20010401 |
| In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. | Cancer chemotherapy and pharmacology 20010401 |
| Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. | Cancer research 20010301 |
| Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). | Cancer research 20010215 |
| Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. | International journal of radiation biology 20010201 |
| Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20010101 |